Gland Pharma receives USFDA approval for first generic Eribulin Mesylate Injection
In a significant advancement for generic pharmaceuticals, Gland Pharma Limited, a company specializing in generic injectable-focused pharmaceutical products, has announced receiving approval from the United States Food and Drug Administration (USFDA) for its Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial. This approval marks a crucial step forward in the availability of generic cancer treatments, […]